Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib mechanisms, successes, and challenges to rational drug development

Hematology/Oncology Clinics of North America

Volumn 16, Issue 5, 2002, Pages 1115-1124

  Demetri, George D ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TUMOR PROTEIN;

ABDOMINAL BLEEDING; ANTINEOPLASTIC ACTIVITY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MUSCLE CRAMP; NAUSEA; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VOMITING; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; FEMALE; FORECASTING; GASTROINTESTINAL TUMOR; GENE DELETION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PHOSPHORYLATION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL; SARCOMA;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; FORECASTING; GASTROINTESTINAL NEOPLASMS; HUMANS; MIDDLE AGED; MULTICENTER STUDIES; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PIPERAZINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; SARCOMA; SEQUENCE DELETION; SIGNAL TRANSDUCTION;

EID: 0036817874     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00052-7     Document Type: Review

References (27)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
2. Mauro MJ, O'Dwyer M, Heinrich MC, et al. STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-34.
3. Perez-Atayde AR, Shamberger RC, Kozakewich HW. Neuroectodermal differentiation of the gastrointestinal tumors in the Carney triad: An ultrastructural and immunohistochemical study. Am J Surg Pathol 1993;17:706-14.
4. Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;153:2008-11.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1-12.
6. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of GISTs: A consensus approach. Hum Pathol 2002;33:459-65.
7. Graadt van Roggen JF, van Velthuysen ML, Hogendoom PC. The histopathological differential diagnosis of gastrointesting stromal tumours. J Clin Pathol 2001;54:96-102.
8. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
9. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001;32:578-82.
10. Goss GA, Merriam P, Manola J, et al. Clinical and pathological characteristics of gastrointestinal stromal tumors (GIST). Proc ASCO 2000;19:559a.
11. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
12. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998;19:323-4.
13. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
14. Lux ML, Rubin BP, Biasé TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
15. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 2001;20:5054-8.
16. Buchdunger E, Zimmermann J, Mett H, et al. Alteration of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
17. Carroll M, Ohno-Jones S, Tamura S, et al. 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90: 4947-52.
18. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
19. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;95:925-32.
20. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
21. Demetri GD, Von Mehren M, Blanke CD, et al. Safety and efficacy of the oral selective tyrosine kinase inhibitor, imatinib mesylate, in patients with advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
22. von Mehren M, Blanke C, Joensuu H, et al. High incidence of durable responses induced by imatinib mesylate (Gleevac) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs). Proc ASCO 2002;21:1608.
23. van den Abbeele A, Badawi RD, Cliché JP, et al. 18F-FDG-PET predicts uresponse to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST) [abstract]. Proc ASCO 2002;21:1610.
24. van den Abbeele A, for the GIST Collaborative PET Study Group. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST) [abstract]. Proc ASCO 2001;20:1444.
25. van Oosterom AT, Judson I, Verweij J, et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
26. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-83.
27. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80 [comment in Science 2001;293:2163].